Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum InMed Pharmaceuticals Inc INM

NDAQ:INM - Post Discussion

InMed Pharmaceuticals Inc > Extreme Volatility
View:
Post by Bullknit101 on Nov 12, 2020 10:04am

Extreme Volatility

We're down 20% - swallowing the dilution pill but I guess at the end of the day, we'll have to wait....
Comment by MeanGreen on Nov 12, 2020 11:01am
A lot of volume on Nasdaq which is nice to see. Let's see how it settles down after a few days 
Comment by djanz12 on Nov 12, 2020 3:16pm
Tough to do a $4.50 US raise with the stock trading at $3.75.
Comment by djanz12 on Nov 12, 2020 5:26pm
I mean $3.30USD. Issue will be repriced. Nobody pays a 36% mark up for stock. More dilution and new lows. Sure hope no directors or officers sold any stock during last weeks manipulation.
Comment by djanz12 on Nov 12, 2020 7:44pm
Head and shoulders pattern targets $2 Cdn and $1.50 USD. Issue will be repriced or wont close. This thing is about to collapse.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities